Trials & Filings

XTANDI Approved for mCSPC

The first oral treatment in three distinct types of advanced prostate cancer –non-metastatic and metastatic castration-resistant prostate cancer (CRPC).

Pfizer Inc. and Astellas Pharma Inc. received approval from the FDA for a supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). In 2019, it is estimated that just over 40,000 men in the United States are living with mCSPC, a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.   With this approval,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters